Srikripa Devarakonda
Stock Analyst at Truist Securities
(2.61)
# 1,321
Out of 4,413 analysts
28
Total ratings
29.63%
Success rate
1.07%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly | Maintains: Buy | $850 → $892 | $781.10 | +14.20% | 1 | May 1, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $25 | $17.94 | +39.35% | 4 | Apr 17, 2024 | |
| CYTK Cytokinetics | Reiterates: Buy | $86 | $61.32 | +40.25% | 3 | Apr 8, 2024 | |
| SRRK Scholar Rock Holding | Reiterates: Buy | $20 | $14.67 | +36.33% | 3 | Apr 3, 2024 | |
| KROS Keros Therapeutics | Reiterates: Buy | $100 | $56.39 | +77.34% | 2 | Mar 13, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $41 → $54 | $33.62 | +60.62% | 2 | Mar 1, 2024 | |
| INCY Incyte | Maintains: Buy | $91 → $84 | $52.05 | +61.38% | 6 | Feb 14, 2024 | |
| VSTM Verastem | Maintains: Buy | $39 → $34 | $9.98 | +240.68% | 5 | Nov 15, 2023 | |
| AFMD Affimed | Maintains: Buy | $80 → $60 | $5.35 | +1,021.50% | 2 | Aug 11, 2023 |
Eli Lilly
May 1, 2024
Maintains: Buy
Price Target: $850 → $892
Current: $781.10
Upside: +14.20%
Edgewise Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $25
Current: $17.94
Upside: +39.35%
Cytokinetics
Apr 8, 2024
Reiterates: Buy
Price Target: $86
Current: $61.32
Upside: +40.25%
Scholar Rock Holding
Apr 3, 2024
Reiterates: Buy
Price Target: $20
Current: $14.67
Upside: +36.33%
Keros Therapeutics
Mar 13, 2024
Reiterates: Buy
Price Target: $100
Current: $56.39
Upside: +77.34%
Kymera Therapeutics
Mar 1, 2024
Maintains: Buy
Price Target: $41 → $54
Current: $33.62
Upside: +60.62%
Incyte
Feb 14, 2024
Maintains: Buy
Price Target: $91 → $84
Current: $52.05
Upside: +61.38%
Verastem
Nov 15, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $9.98
Upside: +240.68%
Affimed
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $5.35
Upside: +1,021.50%